血液恶性瘤中的免疫检查点封锁:当前状态和未来的潜在潜力
Prateek Pophali1, Juan Carlos Varela2, Jacalyn Rosenblatt1
1Division of Hematology and Hematological Malignancies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Frontiers in oncology
|February 7, 2024
概括
免疫检查点抑制剂 (ICI) 在治疗固体瘤方面表现有前途,但在血液癌症中有效性有限. 研究正在探索新的目标和策略,以提高血液恶性瘤的ICI有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 恶性细胞通过激活免疫检查点来逃避免疫监测.
- 免疫检查点抑制剂 (ICI) 通过恢复T细胞抗瘤活性,改变了固体瘤治疗.
- 目前FDA批准的ICI适应症仅限于特定的淋巴瘤,在其他血液性恶性瘤中取得了适度的成功.
研究的目的:
- 审查免疫检查点抑制剂的机制.
- 总结已完成和正在进行的血液恶性瘤中ICI研究的关键发现.
- 讨论血液癌症中ICI治疗的新兴策略和未来方向.
主要方法:
- 已完成和正在进行的临床试验的综合文献综述.
- 对ICI在淋巴瘤,血细胞瘤和骨髓瘤中的疗效和安全性数据的分析.
- 讨论除PD-1/PD-L1和CTLA-4之外的新检查点目标.
主要成果:
- 在针对PD-1/PD-L1和CTLA-4时,ICI在大多数血液性恶性瘤中表现出有限的疗效.
- 目前正在进行的试验正在调查新的检查点 (LAG-3,TIM-3,TIGIT) 和CD47抑制剂.
- 这些新兴疗法的长期安全性和疗效数据正在等待.
结论:
- 提高ICI在血液恶性瘤中的疗效需要探索新的点和组合策略.
- 进一步的研究和临床试验对于优化血液癌症的ICI治疗至关重要.
- 针对新的免疫检查点和巨细胞通路,有可能成为未来的治疗方法.
关键词:
CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47在 CTLA-4 中.现场行动组-3在PD-1中使用PD-1.这是一个紧张的紧张.在TIM-3中,TIM-3是TIM-3.血液学的恶性瘤.免疫检查点抑制剂 免疫检查点抑制剂更多相关视频
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Bone Marrow Sampling and Transplants
331
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
331
Cytotoxic T Cells-mediated Immune Response
917
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
917


